Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rubicon ResearchNSE:RUBICON +0.36%19 Return-on-Tangible-Asset is 14.99% as of Jun. 2026, which is 41% above its 10-year median of 10.62. GuruFocus rates NSE:RUBICON with a GF Score™ of 19/100. The stock has 5 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Rubicon Research ranks better than 86.49% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Rubicon Research's annualizedNet Income for the quarter that ended in Jun. 2026 was ₹3,391 Mil. Rubicon Research's average total tangible assets for the quarter that ended in Jun. 2026 was ₹22,620 Mil. Therefore, Rubicon Research's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 14.99%.
The historical rank and industry rank for Rubicon Research's Return-on-Tangible-Asset or its related term are showing as below:
NSE:RUBICON'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -2.32 Med: 10.62 Max: 13.5
Current: 13.4
During the past 4 years, Rubicon Research's highest Return-on-Tangible-Asset was 13.50%. The lowest was -2.32%. And the median was 10.62%.
NSE:RUBICON's Return-on-Tangible-Asset is ranked better than 86.49% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 2.79
vs NSE:RUBICON: 13.40
Rubicon Research (NSE:RUBICON) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Rubicon Research Return-on-Tangible-Asset Related Terms
Rubicon Research Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Rubicon Research's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:RUBICON vs LLY, JNJ, ABBV: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - General subindustry, Rubicon Research's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rubicon Research Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rubicon Research's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Rubicon Research's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 14.99% mean?
Rubicon Research (NSE:RUBICON) has a Return-on-Tangible-Asset of 14.99% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Rubicon Research and its competitors. This is 41% above median its historical median of 10.62. According to the industry distribution chart, Rubicon Research ranks #136 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 13.5%.
Is Rubicon Research's Return-on-Tangible-Asset too high?
Rubicon Research's current Return-on-Tangible-Asset of 14.99% is 41% above median its 10-year median of 10.62. The Drug Manufacturers industry median Return-on-Tangible-Asset is 2.79. Rubicon Research's value of 14.99% is 437.3% above this industry median. Based on the distribution chart, Rubicon Research ranks #136 out of 1007 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Rubicon Research has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Rubicon Research's Return-on-Tangible-Asset compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Rubicon Research ranks #136 out of 1007 companies for Return-on-Tangible-Asset. This places Rubicon Research in the top 14% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 2.79. Rubicon Research's value of 14.99% is 437.3% above this benchmark. While the company's 10-year median is 10.62 vs. the industry median of 2.79, Rubicon Research has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 2.79, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rubicon Research's current Return-on-Tangible-Asset of 14.99% is 437.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Rubicon Research and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 2.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rubicon Research's current Return-on-Tangible-Asset is 14.99%, which is 41% above median its own 10-year median of 10.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rubicon Research stock overvalued right now?
Rubicon Research (NSE:RUBICON) has a current Return-on-Tangible-Asset of 14.99%. The current Return-on-Tangible-Asset is 14.99%, which is 41% above median its 10-year median of 10.62 and 437.3% above the Drug Manufacturers industry median of 2.79. Rubicon Research's overall GF Score™ is 19/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Rubicon Research (NSE:RUBICON), the current Return-on-Tangible-Asset is 14.99% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rubicon Research Ltd is a pharmaceutical formulations company specializing in developing, manufacturing, and marketing branded specialty and generic prescription products. Starting as a provider of contract formulation development services, the company expanded to operate an oral solids manufacturing facility in India, offering contract development and manufacturing services for regulated markets. The company's diverse product portfolio covers multiple therapeutic areas, including analgesics and pain management, CVS, CNS, hypokalemia, skeletal muscle relaxants, NRT, gastrointestinal, metabolic, and immunosuppressants. The company operates in India, the USA, and other markets, with the majority of its revenue coming from the USA.
19GF Score
Get the complete analysis for NSE:RUBICON
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:RUBICON has been successfully added to your 
